675 – Outcomes on Cabotegravir + Rilpivirine in Suppressed People With HIV (PWH) in TRIO Health US Cohort
Background Cabotegravir+Rilpirivine (CAB+RPV) is the first complete long-acting injectable antiretroviral therapy (ART) for the treatment of HIV for ART-experienced PWH with undetectable viral load (VL <50 copies/mL [cpm]). This study examined the utilization and effectiveness of CAB+RPV in real-world settings in the US. Methods ART-experienced adults with undetectable VL at initiation who received ≥1 CAB+RPV injection…